Prognostic significance of osteosarcopenia and its effects on immune response in patients with stage II/III gastric cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04084-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuki Hirase und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Sarcopenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Canada, Daiichi-Sankyo, Kagoshima University.
Abstract (Originalsprache)
Background
Osteosarcopenia, characterized by muscle loss and osteoporosis, has emerged as a prognostic marker for various malignancies. However, its impact on the immune response in gastric cancer remains unclear. This study aimed to assess the clinical significance of osteosarcopenia and its relationship with the immune microenvironment in patients with advanced gastric cancer.
Methods
This study included 105 patients with pathological stage II/III gastric cancer who underwent gastrectomy between 2018 and 2022. Preoperative computed tomography was used to measure muscle mass and bone density, with sarcopenia and osteoporosis defined as values below the respective standard thresholds. Sarcopenia and osteoporosis were identified when both conditions were present. We explored the relationships between osteosarcopenia, clinicopathological factors, and prognoses. Additionally, immune marker expression was evaluated via immunohistochemistry.
Results
Among the 105 patients, 37 (35%) were diagnosed with osteosarcopenia. This condition significantly correlated with performance status, body mass index, and disease recurrence (all p < 0.05). Overall survival and relapse-free survival were significantly lower in the osteosarcopenia group than those in the non-osteosarcopenia group (all p < 0.05). Moreover, the osteosarcopenia group had significantly fewer CD8-positive, programmed cell death protein 1-positive, and programmed death-ligand 1-positive cells than that of the control group (all p < 0.05).
Conclusions
Our findings suggest that osteosarcopenia is associated with the tumor microenvironment and might serve as a prognostic indicator in patients with advanced gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Digestive Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
- Department of Digestive Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. arigami@m.kufm.kagoshima-u.ac.jp.
Förderung
- Bristol-Myers Squibb Canada
- Daiichi-Sankyo
- Kagoshima University
Zitieren
APA
Hirase, Y., Arigami, T., Matsushita, D., Shimonosono, M., Tsuruda, Y., Sasaki, K., Baba, K., Kawasaki, Y., & Ohtsuka, T. (2025). Prognostic significance of osteosarcopenia and its effects on immune response in patients with stage II/III gastric cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04084-2
Vancouver
Hirase Y, Arigami T, Matsushita D, Shimonosono M, Tsuruda Y, Sasaki K, et al. Prognostic significance of osteosarcopenia and its effects on immune response in patients with stage II/III gastric cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04084-2
BibTeX
@article{Hirase2025,
author = {Hirase, Yuki and Arigami, Takaaki and Matsushita, Daisuke and Shimonosono, Masataka and Tsuruda, Yusuke and Sasaki, Ken and Baba, Kenji and Kawasaki, Yota and Ohtsuka, Takao},
title = {Prognostic significance of osteosarcopenia and its effects on immune response in patients with stage II/III gastric cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04084-2}
}
EUVIMED